<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03968419</url>
  </required_header>
  <id_info>
    <org_study_id>CACZ885V2201C</org_study_id>
    <secondary_id>2018-004813-42</secondary_id>
    <nct_id>NCT03968419</nct_id>
  </id_info>
  <brief_title>This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC.</brief_title>
  <acronym>CANOPY-N</acronym>
  <official_title>A Randomized, Open-label, Phase II Study of Canakinumab or Pembrolizumab as Monotherapy or in Combination as Neoadjuvant Therapy in Subjects With Resectable Non-small Cell Lung Cancer (CANOPY-N)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Novartis Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Novartis</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Major pathological response (MPR) rate of canakinumab given as a neoadjuvant treatment,
      either as single agent or in combination with pembrolizumab, in addition to evaluate the MPR
      rate of pembrolizumab as a single agent. Additionally the dynamics of the tumor
      microenvironment changes on treatment by comparing pre-, on- and post-treatment samples will
      be evaluated.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">November 5, 2019</start_date>
  <completion_date type="Anticipated">January 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 22, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Major Pathological Response (MPR) rate based on Central review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will assess the rate of MPR at the time of surgery in all participants randomized to canakinumab alone and in combination with pembrolizumab arms based on central review.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) of canakinumab</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment &amp; then at 26, 78 and 130 days after last dose</time_frame>
    <description>To characterize the prevalence and incidence of immunogenicity (anti-drug antibodies, ADA) of canakinumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Antidrug antibodies (ADA) of pembrolizumab</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment and then at 26 days after last dose</time_frame>
    <description>To characterize the prevalence and incidence of immunogenicity (anti-drug antibodies, ADA) of pembrolizumab</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR) per investigator assessment using RECIST v1.1</measure>
    <time_frame>From date of randomization to date of surgery up to 6 weeks</time_frame>
    <description>ORR is defined as the proportion of subjects with confirmed best overall response of complete response (CR) or partial response (PR), as per investigator's assessment by RECIST 1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum canakinumab concentration</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), at end of treatment &amp; then at 26, 78 and 130 days after last dose</time_frame>
    <description>To characterize the pharmacokinetics of canakinumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Serum pembrolizumab concentration</measure>
    <time_frame>Predose (0 hour) on Day 1 of Cycles 1 and 2 (Cycle length =21 days), end of infusion on Day 1 Cycle 1, at end of treatment and then at 26 days after last dose</time_frame>
    <description>To characterize the pharmacokinetics of pembrolizumab therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical feasibility rate</measure>
    <time_frame>4 to 6 weeks after first dose</time_frame>
    <description>To assess the rate of the surgical feasibility</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR based on central review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will assess the rate of MPR at the time of surgery in all participants randomized to pembrolizumab monotherapy arm based on central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR based on local review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will assess the rate of MPR at the time of surgery in all randomized participants based on local review in each treatment arm.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Difference in MPR rate based on central review</measure>
    <time_frame>At time of surgery (approximately 4 - 6 weeks after first dose)</time_frame>
    <description>This will estimate the difference in MPR and posterior probability of the difference in MPR â‰¥ 10% between participants randomized to canakinumab + pembrolizumab combination and pembrolizumab alone based on central review.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>MPR rate based on the levels of biomarkers</measure>
    <time_frame>From date of randomization to 130 days after last dose of drug</time_frame>
    <description>Biomarkers include PD-L1, CD8, hs-CRP, hs-IL-6</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">110</enrollment>
  <condition>Non-small Cell Lung Cancer</condition>
  <arm_group>
    <arm_group_label>canakinumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive canakinumab (ACZ885) prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>canakinumab + pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive canakinumab (ACZ885) and pembrolizumab prior to surgery</description>
  </arm_group>
  <arm_group>
    <arm_group_label>pembrolizumab monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive 2 doses of pembrolizumab prior to surgery</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>canakinumab</intervention_name>
    <description>Administered subcutaneously</description>
    <arm_group_label>canakinumab + pembrolizumab</arm_group_label>
    <arm_group_label>canakinumab monotherapy</arm_group_label>
    <other_name>ACZ885</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>pembrolizumab</intervention_name>
    <description>200mg administered intravenously every 3 weeks</description>
    <arm_group_label>canakinumab + pembrolizumab</arm_group_label>
    <arm_group_label>pembrolizumab monotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion criteria:

          -  Histologically confirmed NSCLC stage IB-IIIA (per AJCC 8th edition), deemed suitable
             for primary resection by treating surgeon, except for N2 and T4 tumors.

          -  Subject must be eligible for surgery and with a planned surgical resection in
             approximately 4-6 weeks (after the first dose of study treatment).

          -  A mandatory newly obtained tissue biopsy from primary site is required for study
             enrollment. An archival biopsy is also acceptable if obtained up to 5 months before
             first day of study treatment and if the subject did not go through antineoplastic
             systemic therapies between biopsy collection date and beginning of study treatment.

        Note: Aspirates will not be accepted.

        - Eastern Cooperative oncology group (ECOG) performance status of 0 or 1.

        Key exclusion criteria:

          -  Subjects with unresectable or metastatic disease.

          -  History of severe hypersensitivity reactions to monoclonal antibodies, which in the
             opinion of the investigator may pose an increased risk of serious infusion reaction

          -  Subjects who received prior systemic therapy (including chemotherapy, other
             anti-cancer therapies and any other antibody or drug specifically targeting T-cell
             co-stimulation or immune checkpoint pathways) in the past 3 years before screening

          -  Active autoimmune disease that has required systemic treatment in the past 2 years
             prior to randomization. Control of the disorder with replacement therapy is permitted

          -  Subject with suspected or proven immunocompromised state or infections

        Other protocol-defined inclusion/exclusion criteria may apply.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Novartis Pharmaceuticals</last_name>
    <role>Study Director</role>
    <affiliation>Novartis Pharmaceuticals</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>1-888-669-6682</phone>
    <email>novartis.email@novartis.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Novartis Pharmaceuticals</last_name>
    <phone>+41613241111</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>University Of California</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92037</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsey K Middleton</last_name>
      <phone>858-622-5855</phone>
      <email>lmiddleton@mednet.ucla.edu</email>
    </contact>
    <investigator>
      <last_name>Edward B Garon</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baptist MD Anderson Cancer Center</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32207</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sarah Sakin</last_name>
      <phone>614-657-1463</phone>
      <email>sarah.sakin@bmcjax.com</email>
    </contact>
    <investigator>
      <last_name>John Vu</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Montpellier cedex 5</city>
        <state>Herault</state>
        <zip>34059</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Paris</city>
        <zip>75679</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Bad Berka</city>
        <zip>99437</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Giessen</city>
        <zip>35392</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Halle (Saale)</city>
        <zip>06120</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Koeln</city>
        <zip>51109</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Thessaloniki</city>
        <zip>57001</zip>
        <country>Greece</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Torokbalint</city>
        <state>Pest</state>
        <zip>2045</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Budapest</city>
        <zip>1121</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Miskolc</city>
        <zip>3526</zip>
        <country>Hungary</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Kashiwa</city>
        <state>Chiba</state>
        <zip>277 8577</zip>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Hertogenbosch</city>
        <zip>5200</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Maastricht</city>
        <zip>6229 HX</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Utrecht</city>
        <zip>3508 GA</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Omsk</city>
        <zip>644013</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>197022</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>St Petersburg</city>
        <zip>195271</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Jaen</city>
        <state>Andalucia</state>
        <zip>23007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Oviedo</city>
        <state>Asturias</state>
        <zip>33006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Madrid</city>
        <zip>28034</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <zip>110</zip>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Izmir</city>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sakarya</city>
        <zip>54290</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Novartis Investigative Site</name>
      <address>
        <city>Sihhiye / Ankara</city>
        <zip>06100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Hungary</country>
    <country>Japan</country>
    <country>Netherlands</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Taiwan</country>
    <country>Turkey</country>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>May 15, 2019</study_first_submitted>
  <study_first_submitted_qc>May 29, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 30, 2019</study_first_posted>
  <last_update_submitted>June 19, 2020</last_update_submitted>
  <last_update_submitted_qc>June 19, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>ACZ885</keyword>
  <keyword>canakinumab</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>NSCLC</keyword>
  <keyword>non-small cell lung cancer</keyword>
  <keyword>non small cell lung cancer</keyword>
  <keyword>early stage NSCLC</keyword>
  <keyword>squamous</keyword>
  <keyword>non-squamous,</keyword>
  <keyword>MPR</keyword>
  <keyword>major pathological response</keyword>
  <keyword>hs-CRP</keyword>
  <keyword>PD-L1</keyword>
  <keyword>hsCRP</keyword>
  <keyword>surgery</keyword>
  <keyword>neo-adjuvant</keyword>
  <keyword>neo adjuvant</keyword>
  <keyword>CD8</keyword>
  <keyword>hs-IL-6</keyword>
  <keyword>CANOPY</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Novartis is committed to sharing with qualified external researchers, access to patient-level data and supporting clinical documents from eligible studies. These requests are reviewed and approved by an independent expert panel on the basis of scientific merit. All data provided is anonymized to respect the privacy of patients who have participated in the trial in line with applicable laws and regulations.
This trial data is currently available according to the process described on www.clinicalstudydatarequest.com.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

